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STATEMENT OF RELEVANCE: 
Molecular subgrouping of hepatocellular carcinoma (HCC) is challenging due to lack of tissue 
sampling, and profiling the HCC mutational landscape by cfDNA may be particularly attractive 
given the challenge of obtaining liver biopsies. We report the largest USA cohort, using a CLIA-
certified assay approved for clinical practice. Our results demonstrate significant trends between 
alterations and risk factors - metabolic syndrome and PDGFRA, HBV and ERBB2, HCV and 
BRCA1. In addition, we observed a high percentage of potentially actionable genomic alterations, 
suggesting clinical utility for this technology in HCC. 
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ABSTRACT 
Purpose: Molecular profiling has been used to select patients for targeted therapy and determine 
prognosis. Noninvasive strategies are critical to hepatocellular carcinoma (HCC) given the challenge 
of obtaining liver tissue biopsies.  
Experimental Design: We analyzed blood samples from 206 HCC patients using comprehensive 
genomic testing (Guardant Health, CA) of circulating tumor DNA (ctDNA). 
Results: 153/206 (74.3%) were men; median age, 62 years (range, 18-91 years). 181/206 patients 
had >1 alteration. The total number of alterations was 680 (non-unique); median number of 
alterations/patient was 3 (range, 1-13); median mutant allele frequency (% cfDNA), 0.49% (range 
0.06 – 55.03%). TP53 was the common altered gene (>120 alterations (non-unique)) followed by 
EGFR, MET, ARID1A, MYC, NF1, BRAF, and ERBB2 (20-38 alterations (non-unique)/gene). Of the 
patients with alterations, 56.9% (103/181) had >1 actionable alterations, most commonly in MYC, 
EGFR, ERBB2, BRAF, CCNE1, MET, PIK3CA, ARID1A, CDK6, and KRAS. In these genes, 
amplifications occurred more frequently than mutations. Hepatitis B (HBV)-positive patients, were 
more likely to have ERBB2 alterations, 35.7% (5/14) versus 8.8% HBV- negative (p=0.04).  
Conclusions: This study represents the first large-scale analysis of blood-derived ctDNA in HCC in 
USA. The genomic distinction based on HCC risk factors and the high percentage of potentially 
actionable genomic alterations suggests potential clinical utility for this technology. 
 
Keyword: cell-free DNA; hepatocellular carcinoma; molecular profiling  
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INTRODUCTION 
Recent technological advances in molecular diagnostics have allowed for the study of 
solid malignancies through non-invasive blood sampling. Importantly, intact circulating tumor 
cells (CTCs) and cell-free DNA (cfDNA) [leukocyte-derived and tumor-derived (circulating tumor 
DNA; ctDNA)] can now be interrogated through advanced sequencing methods in order to 
identify somatic mutations that may be druggable targets for future therapies1, 2. Although cfDNA 
and ctDNA are similar in that they both derive from cell lysis and apoptosis3, ctDNA is the 
fraction of cfDNA, which can range from <0.1% to >10%4, specifically derived from primary or 
metastatic tumors5. Therefore, profiling the mutational landscape of ctDNA from solid tumors 
may represent a particularly attractive method for identifying tumor-associated somatic 
mutations. Applications that can be envisioned to be of clinical utility for hepatocellular 
carcinoma (HCC) include detection of genomic changes, mutational analysis, prognostication, 
oncogenic pathway determination, prediction/monitoring of treatment response, drug resistance 
alterations, and identification of mechanisms of malignant/metastatic transformation based on 
underlying risk factor and genetic predisposition.  
 CtDNA has been found to be inversely correlated with HCC prognosis6and shorter 
overall survival7. Although several studies have investigated the global alterations in cfDNA of 
HCC8-13, the small number of patients and heterogeneity of demographics and geographic 
locations posed a challenge to the application of this methodology in the US12, 13. 
Therefore, the purpose of the current study was to examine a large multi-institutional 
cohort of HCC tumors with a CLIA-certified cfDNA technology that is currently used in practice 
and to identify the mutational landscape that may be contributing to HCC tumorigenesis for the 
purpose of selecting patients for targeted therapy trials. This investigation represents the largest 
reported series of HCC patients analyzed to date for the genomic portraits derived from blood-
derived cfDNA.  
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METHODS 
Patients:  
During the period extending from November 2014 to July 2016, 219 patients with 
advanced HCC underwent blood-derived cfDNA testing by Guardant Health (Redwood City, 
CA). The diagnosis of HCC was established either by histopathological examination or by 
characteristics imaging findings, following clinical guidelines by the American Association for the 
Study of Liver Disease (AASLD)14. The majority of the patients were from the following 4 
institutions: MD Anderson Cancer Center (MDACC; 37 patients), University of California San 
Diego, Moores Cancer Center (UCSD; 36 patients), Washington University School of Medicine-
Siteman Cancer Center (18 patients), and University of California San Francisco-Helen Diller 
Family Comprehensive Cancer Center (UCSF) (11 patients). The remaining patients were from 
other US institutions. From the 219 patients, 12 had serial testing.  For patients who had more 
than one test, only the first test result was considered. The analysis and consent of patients in 
this cohort followed guidelines of various institutional review boards and clinical protocols, as 
follows: MDACC: NCT01772771- Molecular Testing for the MDACC Personalized Cancer 
Therapy Program; UCSD: NCT02478931 (PREDICT)-Study of Personalized Cancer Therapy to 
Determine Response and Toxicity; Washington University School of Medicine-Siteman Cancer 
Center: WU IRB protocol 201606097, A retrospective analysis of circulating cell free DNA in 
patients with gastrointestinal malignancies; UCSF, UCSF IRB# 12-09576 Hepatobiliary Tissue 
Bank and Registry. The latter two institutional IRB approvals were for non-therapeutic/non-
interventional use and hence are not registered in clinicaltrials.gov. The study was conducted in 
concordance with the Declaration of Helsinki.  
Demographic information (i.e., gender, age) and date of blood collection were available 
for all patients. Additional patient information was requested from the institutions that 
contributed more than 10 patients for cfDNA testing (UCSD, MDACC, Siteman Cancer Center, 
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and UCSF). The information requested was as follows: (i) confirmation of HCC diagnosis; (ii) 
risk factor information, such as hepatitis A, B, and C status, non-alcoholic steatohepatitis 
(NASH), alcoholic liver disease, and metabolic syndrome; (iii) relevant clinicopathologic 
information including Child-Pugh score, Cancer of the Liver Italian Program (CLIP), Barcelona 
Clinic Liver Cancer (BCLC), Tumor-Node-Metastasis (TNM) Staging, and treatment status at 
time of ctDNA testing. Metabolic syndrome as established as a clinical diagnosis as per 
guidelines by the 2001 National Cholesterol Education Program ATP III15. The diagnosis of 
NASH was established by pathologic diagnosis of NASH in patients with available clinical data.  
 
 
Comprehensive genomic testing in plasma: 
cfDNA was extracted from whole blood collected in 10 mL Streck tubes. Samples were 
shipped to a Clinical Laboratory Improvement Act (CLIA)-certified, College of American 
Pathologists-accredited laboratory (Guardant Health, Redwood City, California). After double 
ultracentrifugation, 5 ng – 30 ng of cfDNA was isolated for digital sequencing as previously 
described12, 13, 16.  
 Cell-free DNA fragments, both leukocyte- and tumor-derived, were simultaneously 
sequenced. The variant allele fraction (VAF) was calculated as the proportion of cfDNA 
harboring the variant in a background of wild-type cell-free DNA. The analytical sensitivity 
allowed detection of 1-2 mutant fragments in a 10 ml blood sample (0.1% limit of detection) with 
analytic specificity > 99.9999%. Twelve CNAs were reported as the absolute gene copy number 
in plasma. Since most cfDNA is leukocyte-derived, the gene copy number is generally 2.0. 
Tumor-derived DNA shed into the bloodstream raises this value but, due to the relative 
proportions of tumor-derived versus leukocyte-derived cfDNA, it is typically a minor contributor. 
Gene copy number in plasma is thus a function of both copy number in tissues and the degree 
to which tumor DNA is shed into circulation. Plasma copy number of 2.5-4.0 is reported as ++ 
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amplification and >4.0 as +++, representing the 50th-90th and >90th percentile, respectively of 
all CNA calls in the Guardant360 database12, 13, 16. 
Over the course of the study, the panel composition expanded from 54 to 68 to 70 
genes. The initial 54-gene panel consisted of complete exon coverage or critical exon coverage 
in 54-cancer related genes, and amplifications in 3 genes. In the 68-gene panel, 8 genes were 
retired from the single nucleotide variation (SNV) gene set, while coverage of gene 
amplifications expanded from 3 to 16 genes, and detection of fusions in 4 genes, and insertions 
or deletion of bases (indels) in 1 gene. The 70-gene panel includes all NCCN somatic genomic 
targets, including complete or critical exon coverage in 30 and 40 genes, respectively; 
amplifications in 18 genes, fusions in 6 genes, and indels in 3 genes [Supplementary Table 1]. 
Seven patients were tested on the 54-gene panel was used, eighty-six on the 68-gene version 
of the original, and one-hundred-forty-two on the 70-gene panel version [Supplementary Table 
2]. 
 
Actionable genes and variants defined 
To determine whether an alteration was actionable or not, we referenced the actionable 
gene list set in place by the Institute for Personalized Cancer Therapy-Precision Oncology 
Decision Support (PODS) team at MD Anderson Cancer Center17. By these standards, a gene 
is considered actionable if there is supporting evidence that such gene is a driver of 
tumorigenesis, wherein actionability of the gene can refer to either sensitivity and/or resistance 
to a drug(s), and sensitivity and/or resistance can be inclusive of all alterations types or specific 
to alteration classes, i.e., applicable to amplifications, but not mutations. Furthermore, there 
must be a clinically available agent targeting such gene, and for a specific agent, there must be 
at least pre-clinical evidence that supports its role in targeting the specific gene. While the 
PODS team aims at maintaining the actionable gene list as comprehensive and up to date as 
possible, we relied heavily on the availability of a drug in the context of clinical trial at MDACC. 
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However, we acknowledge that drug availability and trials varies greatly by institution. Finally, 
the actionability of a gene can be in the context of tumor type(s). For example, in colorectal 
cancer, the use of the EGFR monoclonal antibodies cetuximab and panitumumab is 
contraindicated in tumors with activating KRAS mutations, specifically those in codons G12 and 
G13 (FDA label)18-20. Hence, KRAS is deemed actionable for treatment with MEK inhibitors in all 
tumor types. However, in the case of colorectal cancer, it is also deemed actionable for 
resistance to cetuximab and panitumumab21. At the moment, there are no HCC-specific 
actionable gene. 
Based on the aforementioned criteria, the following genes were considered actionable 
based on their sensitivity towards respective targeted agents: AKT1, ALK, ARAF, ARID1A, 
ATM, BRAF, BRCA1, BRCA2, CCND1, CCND2, CDK4, CDK6, CDKN2A, CDKN2B, EGFR, 
ERBB2, FGFR1, FGFR2, FGFR3, HRAS, IDH1, IDH2, JAK2, JAK3, KIT, MAP2K1, MAP2K2, 
MET, MPL, MYC, NF1, NOTCH1, NRAS, NTRK1, PDGFRA, PIK3CA, PTEN, PTPN11, RET, 
ROS1, SMO, STK11, and TSC1.  
The following genes were deemed actionable based  on context-specific criteria: CCNE1 
(sensitivity to CDK2 inhibitors; resistance to CDK4/6 inhibitors); ESR1 (presence is sensitizing 
to hormone therapy, mutations cause resistance to anti-hormone therapy); KRAS (sensitivity to 
MEK inhibitors; resistance to cetuximab and panitumumab in colorectal and erlotinib, and 
gefitinib in NSCLC; NRAS (sensitivity to MEK inhibitors, resistance to cetuximab and 
panitumumab); RAF1 (activating alterations cause sensitivity to MEK inhibitors and resistance to 
RAF inhibitors; inactivating alterations cause resistance to dasatinib). Only AR and RB1 were 
deemed actionable solely because of their resistance to anti-hormone therapy and to CDK4/6 
inhibitors, respectively. 
At the time of analysis, several genes included in the Guardant panel were denoted as 
non-actionable including: TP53, CTNNB1, APC, GNAS, NFE2L2, MLH1, RIT1, SMAD4, 
HNF1A, CDH1, GATA3, VHL, FBXW7, and RhoA. To note, some investigators, including co-
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authors on this manuscript, have considered TP53 actionable for Wee-1 or VEGF/VEGFR 
inhibitors 22-24. Since this remains a matter of debate, TP53 was not considered actionable in 
this paper. Likewise, since the initial analysis, MLH1 has also become actionable based on 
FDA-approval of nivolumab and pembrolizumab in 2017. Finally, variants found in actionable 
genes but which lacked any supporting, functional evidence were designated as “variants of 
unknown functional significance.” A comprehensive list of all genes considered and their 
actionability is included in Supplementary Table S1b.  
Statistical analysis 
The distribution of each continuous variable was summarized by its mean, standard 
deviation, and range. The distribution of each categorical variable was summarized in terms of 
its frequencies and percentages.  Continuous variables were compared between groups by 
Wilcoxon rank sum test, and for categorical data the comparison was conducted by Fisher 
Exact test. Heat map with dendogram was generated to explore and visualize the gene 
mutation/amplification relationship along with the corresponding various risk factors. The 
relationship between gene types with regard to mutation and amplification as well as 
synonymous and targetable status was evaluated with Spearman’s rank correlation and 
displayed in the correlation matrix in which the non-significant correlations are marked with 
“blank” in the graph [Figure 6]. All computations were carried out in SAS version 9.3 and R 
version 3.13. 
 
RESULTS  
Patient Characteristics:  
A cohort of 219 patients was enrolled in the study. The median age was 62.3 years 
(range: 18-91; 160 males and 59 females). Irrespective of gene actionability, the median 
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number of alterations per patient was 3 (range: 1-13); the median allele frequency (AF) of 
altered cfDNA (%cfDNA) was 0.49% (range: 0.06-55.03).  
After further evaluation, it was determined that 13 of these patients had a diagnosis 
other than HCC, namely, fibrolamellar HCC, cholangiocarcinoma or mixed 
HCC/cholangiocarcinoma. This determination was based on Liver Imaging Reporting and Data 
System (LI-RADS) and tumor markers for HCC, while fibrolamellar and mixed 
HCC/cholangiocarcinoma were mostly confirmed by biopsy. These patients were excluded from 
further analysis. In addition, for the patients who had more than one cfDNA test ordered (n=12 
patients), only the first order was considered for further analysis. After exclusion of these unique 
cases, as well as the non-HCC cases, the initial data set was reduced from 219 to 206 patients, 
and from 777 to 680 alterations [Figure 1a-d]. 
Overall distribution of alteration types  
The majority of patients (87.8%=181/206) had at least one alteration; only 12.2% 
(25/206) had no alterations [Figure 1a]. A total of 680 alterations (non-unique) were detected 
among the former patient population, of which 10.5% (72/680) were synonymous/silent in 
nature, and 16% were amplifications (109/680). The remaining 73.3% of alterations (499/680) 
consisted of indels, missense, nonsense, and splice variants. A fraction of these alterations 
(214/499), were classified as “variants of unknown functional significance” (VUS) due to lack of 
supporting evidence for their functionality. The remaining variants (285/499) were broadly 
categorized as “mutations”, and made up 42% (285/680) of the total alterations identified 
[Figure 1b]. 
Further analysis of the 42% of alterations that made up the “mutation” category revealed 
that 53% of these alterations occurred within actionable genes (actionable mutations) while the 
remaining 47% occurred within genes not considered actionable (non-actionable mutations) at 
the time of analysis [Figure 1c]. On the other hand, all of the reported amplifications occurred 
within actionable genes. After accounting for synonymous alterations, variants of unknown 
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significance (VUS), and mutation in non-actionable genes, the total number of actionable 
alterations was 209 out of the initial 680 (non-unique) alterations identified [Figure 1d]. ). Of the 
patients with alterations, 56.9% (103/181) had >1 actionable alterations.  
 
Most frequently mutated genes identified  
We assessed the overall molecular landscape of the 181 HCC patients with detected 
alterations, both in terms of number of alterations reported per gene and number of patients per 
gene. Additionally, to assess the true utility of cfDNA findings, in terms of their potential for 
guiding clinical decisions, genes were parsed into “actionable” and “non-actionable genes”, as 
defined above (see Methods section for details). Inclusive of all alteration types (i.e., 
synonymous, VUS), the most frequently altered genes (≥20 events/gene) were as follows: within 
actionable genes--EGFR, MET, ARID1A, MYC, NF1, BRAF, and ERBB2; among non-actionable 
genes--TP53, followed by CTNNB1 and APC [Figure 2a].  Overall, TP53 was the most 
commonly altered gene, with >120 alterations. By comparison, EGFR had 38 alterations. Of 
note, the gene panel evolved over the course of this study, hence the number of patients 
evaluated for each of the genes varied depending on the panel available at that time. Moreover, 
detection of copy number variations was limited to amplifications in a subset of genes (see 
Material and Methods and Supplementary Table S1a and S2 for details).  
Exclusion of non-actionable alterations, i.e., VUS and synonymous alterations, further 
reduced the total number of alterations from 680 alterations to 209 alterations. Moreover, the 
patient population was also reduced from 181 to 103 patients, as many patients only had 
alterations detected within non-actionable genes, or all alterations were synonymous or VUS. 
Among the 103 patients with actionable alterations, the most commonly altered genes (≥10 
patients/gene) were MYC, EGFR, ERBB2, BRAF, CCNE1, MET, PIK3CA, ARID1A, CDK6, and 
KRAS. Likewise, amplifications were more common than mutations among the top genes 
[Figure 2b].  
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Gene correlation matrices to visualize co-expression and mutual exclusivity of genes 
with alterations detected 
Two correlation matrices were generated, independent of the availability of risk factor 
information: the first matrix considered all confirmed HCC patients with alterations detected, and 
included all alterations types (synonymous, VUS, mutations, amplifications) in both actionable 
and non-actionable genes. This amounted to 181 patients and 62 genes analyzed [Figure 2c]. 
The premise of this matrix was to allow an overall appreciation of all alterations identified. For 
more hypothesis-generating analysis, the second matrix, which focused only on mutations and 
amplifications within actionable genes (see S1b), and excluded synonymous and VUS 
alterations [Figure 2d] was generated. Application of these exclusion criteria reduced the initial 
correlation matrix from 181 to 103 patients, and from 62 to 36 actionable genes. Concordance 
estimates and 95% intervals (Cohen’s kappa) for each pair of genes were generated to better 
understand any association in terms of co-expression or mutual exclusivity of genes analyzed. 
In this analysis, any value <0 indicated no agreement, 0 – 0.20 slight agreement, 0.21–0.40 as 
fair agreement, 0.41–0.60 as moderate agreement, 0.61–0.80 as substantial agreement, and 
0.81–1 as almost perfect agreement [Figure 2c-d]. Firm conclusions were not possible with 
these matrices, given the small sample size, but hypothesis-generating observations could be 
deduced. 
 
Identifying patients with alterations in actionable genes and available risk factor data 
To understand if molecular findings correlated with any of the risk factors commonly 
observed among patients diagnosed with HCC, we requested additional patient information from 
institutions having >10 HCC participants, as detailed under Methods. These included: 
University of California San Diego Moores Cancer Center: 36 patients, 48 orders; MD Anderson 
Cancer Center: 37 patients, 37 orders; Siteman Cancer Center: 18 patients, 19 orders; and 
        
 15 
University of California San Francisco Comprehensive Cancer Center: 11 patients, 11 orders) 
for a total of 103 patients.   
The 13 non-HCC cases previously excluded were identified from within this population. 
Hence, the final number of patients from participating institutions was 89 patients, of which 82 
patients had alterations detected while 7 had none [Figure 3]. We again parsed this subset of 
alterations into actionable or non-actionable groups; the latter included synonymous alterations, 
VUS, and non-actionable genes. We identified a subset of patients (n=34) who only had 
alterations detected in non-actionable genes or the alteration type was non-actionable, in the 
case of synonymous or VUS. Ultimately, this reduced the patient population with alterations 
from 82 to 48 patients contributing, for a total of 98 alterations (non-unique) in 31 actionable 
genes. This small subset of patients was statistically evaluated for their correlation with risk 
factors contributing to HCC, and consisted of 14 women, 34 men, mostly Caucasian patients 
(n=30) followed by Hispanic (n = 8), Asian (n = 5), Black (n = 2), Native American (n = 1) and 
other (n = 2). Nineteen patients were reported to have alcoholic liver disease, 8 had confirmed 
non-alcoholic steatohepatitits (NASH) and 10 had metabolic syndrome. Staging information as 
classified by Child-Pugh Score (CPS), Barcelona Clinic Liver Cancer staging system (BCLC), 
CLIP, and/or TNM staging was requested. There were 27 patients with Child-Pugh Score of A: 
(5-6, well compensated), 13 with stage B: (7-9, significant functional compromise), and 1 with C: 
(10-15, decompensated). Six patients had an unknown BCLC classification, while 1 was 
classified as stage A, 4 as stage B and 37 as stage C. Hepatitis A was reported in 12 patients; 
hepatitis B in 14 patients; and hepatitis C in 17 patients. There were only a handful of cases with 
both hepatitis A & B (n=4), hepatitis B & C (n=6) or hepatitis A & C (n=7). [Supplementary 
Table 3, Supplementary Figure 1a-d]. 
Although this smaller subset (only patients with available risk factor information and only 
actionable genes) included only 48/206 patients, it maintained the overall molecular landscape 
of the larger subset (see Figure 2a-b). Whereas in the overall population the top 10 most 
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frequently altered actionable genes were MYC, EGFR, ERBB2, BRAF, CCNE1,MET, PIK3CA, 
ARID1A, CDK6, and KRAS, in this subset of patients (n= 48) the top 10 most frequently altered 
actionable genes were: EGFR, ERBB2, MET, CCNE1,MYC, BRAF, CCND1, CDK6, FGFR2, 
and ARID1A [Figure 4a-b]. Hence, this subgroup should be considered a suitable and 
representative model of the molecular profile of circulating cell-free DNA in patients with 
hepatocellular carcinoma. 
 
Correlation of risk factors with alterations identified 
Significant differences were noted in the molecular profile of patients based on their 
underlying hepatic reserve and risk factors for HCC. Among patients with metabolic syndrome, 
30% (3/10) had alterations detected in PDGFRA (p=0.0113), while patients without metabolic 
syndrome (n=30) had no alterations in this gene. In terms of hepatitis status, 35.7% (5/9) of 
patients with hepatitis B had alterations in ERBB2 (p=0.0365), and 16.7% (3/18) of patients with 
hepatitis C had alterations in BRCA1 (p=0.0472). Hepatitis B and Hepatitis C negative patients, 
did not have any alterations in these respective genes. In addition, 23.1% (3/13) of patients with 
Child-Pugh score B had alterations in PIK3CA (p=0.0341) versus 0% (0/27) Score A (0/27) or C 
(0/1) (p=0.03). Heat map with dendogram was generated to better visualize and study the gene 
mutation/amplification relationships along with the corresponding various risk factors. The 
relationships between gene types, with regard to mutation and amplification as well as 
synonymous and targetable status, was evaluated with Spearman’s rank correlation and 
displayed in the correlation matrix in which the non-significant correlations are marked with 
“blank” in the graph. All computations were carried out in SAS version 9.3 and R version 3.13. 
[Figure 5-6; Supplementary figure 2a-c]. 
 
DISCUSSION 
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In the vast majority of patients, HCC comprises a two-disease state; HCC tumors and 
concomitant liver disease. Therefore, HCC staging/prognostication systems take into account 
tumor parameters in addition to hepatic reserve grade, manifested by Child-Pugh classification. 
While mounting evidence in the literature suggests different molecular pathogenesis pathways 
based on the degree of liver fibrosis and underlying HCC risk factors, this has not been 
translated into defining molecular subclasses in HCC. The challenge to defining molecular 
nosology is largely due to lack of access to tissue sampling in HCC, given the risk of bleeding 
due to concomitant coagulopathy and thrombocytopenia in patients with advanced fibrosis and 
portal hypertension. This bleeding risk led to the development and wide acceptance of 
guidelines to diagnose HCC without tissue sampling25. Therefore, despite recent advances in 
our understanding of HCC molecular profiling based on tissue sampling26, firm conclusions and 
biomarker integration into HCC staging were not achieved due to major challenges in 
prospective validation studies that are powered to study risk factor-specific HCC. Liquid biopsies 
could bridge this gap, given the practicality of obtaining them in this patient population, and are 
expected to help advance the field of molecular prognostication and patient selection in targeted 
therapy trials. The current study represents a step towards achieving this major goal given our 
important observations related to specific common risk factors in HCC. This study also 
represents the largest US cohort ever reported. Hence, our correlative findings of molecular 
alterations, as they relate to specific risk factors and demographics, highlight the importance of 
cfDNA methodology in HCC and warrant future validation and exploration on its utility. 
Chronic infection with hepatitis B with its incorporation into the human genome is a 
common HCC risk factor, particularly in Asia. The pathogenesis can be due to oncogenic viral 
proteins or insertional mutagenesis. The mutational spectrum in HCC arising from hepatitis B 
infection is known to be enriched with TERT, CCNE1, and MLL4 due to insertional events, while 
hepatitis C infection is typically chronic and leads to chronic inflammatory cascade events in the 
microenvironment and mutations.  
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Interestingly, our study showed statistically significant associations between certain 
alterations and specific risk factors, such as metabolic syndrome and PDGFRA (p=0.0113), 
HBV and ERBB2 (p=0.0365), HCV and BRCA1 (p=0.0472), and Child-Pugh score B and 
PIK3CA (p=0.0341). This relationship between gene types with regard to alteration type, risk 
factor, and targetable status was evaluated with Spearman’s rank correlation and displayed in 
the correlation matrix. However, given the small number of patients in each category, we 
consider these findings as hypothesis-generating associations that should be studied in future 
validation studies However, given the small number of patients in each category, we consider 
these findings as hypothesis-generating associations that should be studied in future validation 
studies. For example, while ERBB2 dysregulation is not known to be a significant driver or 
hallmark of HCC, upregulation, correlation with HCC poor outcome, and cell line data suggests 
that HBV interacts with ERBB2 and ERBB3 resulting in protein stabilization [20,21]. Similarly, 
dysregulation of BRAF, BRCA1, MET, CDK6, ARID1A, CCNE1, EGFR, FGFR1, MYC, and 
NOTCH1 correlated with a history of HCV in our study [Supplementary Figure 4a-d]. In the case 
of BRCA1, while there is an exhaustive amount of literature supporting the role of BRCA1 in 
breast and ovarian tumor types, less is known about the role of BRCA1 in HCC, much less in 
regards to its role in HCV affected HCC patients. Nonetheless, one whole genome-sequencing 
analysis of 88-matched HCC tumor/normal tissue samples, reported that BRCA1 alterations 
were identified in 1.1% of HCC patients 27. By comparison, our study using cfDNA assay 
identified BRCA1 alterations in 4 of 212 patients (1.8%) by ctDNA. Although this is not direct 
evidence for BRCA1 in HCV in HCC, overall these findings are consistent with NGS results in 
solid tumor testing. Furthermore, increasing evidence supports the role of common molecular 
signatures across distinct tumor types 28-30. Hence, there is the potential that BRCA1 and/or 
other genes that have specifically been implicated in other tumor types, may also be relevant to 
HCC. 
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Notably, alterations in TERT promoter and in CTNNB1 gene were reported among the 
most frequent alterations in HCC31, and in particular viral hepatitis-related HCC32. Similarly, our 
data indicated the high prevalence of CTNNB1 mutations but did not confirm the hepatitis status 
correlation, most likely because of the relatively small sample size of patients with available risk 
factors for analysis 33-38. 
One of the major strengths of our study is the large number of patients representing 
numerous US institutions driven by samples submitted prospectively to aid in therapeutic 
decision making using a CLIA-certified assay approved for clinical practice. Moreover, almost 
half of the patients had risk factors. Another major advantage to our study is the critical 
importance to assessing ctDNA in HCC patients, where, obtaining initial and repeat tissue 
sampling may be challenging as previously mentioned. However, the study has some 
limitations. First, firm conclusions of the correlation with risk factors were not possible given the 
small number of patients with available risk factors from five institutions. However, the pattern of 
the alterations was similar to the overall cohort. Second, the cfDNA panel is not as 
comprehensive as some tissue molecular profiling panels. However, the panel used is clinically 
driven in that it is designed to identify somatic alterations in 73 genes, primarily focused on 
genomic alterations that are associated with 1) FDA-approved targeted therapies, 2) targeted 
therapies in late stage clinical trials, 3) known predictive or prognostic value, or 3) informative of 
the presence of cfDNA. It is also important to note that the Guardant360 assay reports out only 
somatic alterations. Mutant allele fractions (MAF) are reported quantitatively for somatic single 
nucleotide variants (SNVs) of clinical significance and distinguished from heterozygous and 
homozygous germline variants by their low concentrations, which are filtered out by the 
Guardant360 molecular tumor board39. Another study limitation was that there was no direct 
comparison with tumor tissue, in large part because of the difficulty in doing biopsies in HCC; 
therefore, our work reflects current clinical practice, in which the imaging diagnosis of HCC in 
the appropriate setting without tissue diagnosis is widely adopted in both academic and 
        
 20 
community centers. However, surgical resection may be a source of tissue in patients - this 
procedure is more frequent in South East Asia where HBV patients with HCC may not have 
cirrhosis. Finally, we acknowledge the definition of actionability is dynamic and institution-
dependent, and data on enrollment on targeted trials based on cfDNA results was not available. 
Prospective studies using ctDNA profiling to guide therapy decisions are warranted. 
Notwithstanding the fact that further validation with solid tumor testing results is 
necessary, we conclude that cfDNA testing is a valid methodology for HCC molecular profiling 
given the abundance of ctDNA observed in this, the largest collection of US-based blood 
samples. While this direct comparison was not possible within this patient population, as few 
patients had solid tumor testing results available, comparison to the findings reported recently 
by the Cancer Genome Atlas initiative40  and other prior studies34, 41, are greatly encouraging, 
considering the limitations of the current sample population and the limited comprehensiveness 
of the cfDNA gene panel. In both the TCGA results and this study, the most commonly altered 
genes were TP53 and CTNNB1, while amplifications were most commonly observed in MET 
and CCND1. Moreover, the interesting molecular alteration findings related to specific HCC risk 
factors, if validated, could also pave the way for developing a molecularly driven HCC 
classification, and could aid in stratification for clinical trials.  Indeed, genomically driven trials, 
both ongoing and completed, have begun to allow enrollment based on cfDNA test results. In 
HCC specifically, Ikeda et al recently published their findings on the clinical utility of cfDNA 
testing in HCC, reporting 79% of tested patients having at least one clinically actionable 
alteration identified via cfDNA testing, with two patients showing good clinical response to 
matched targeted therapies42. Nonetheless, future validation studies with larger numbers of 
patients with available patient characteristic data are essential for directing HCC translational 
efforts. Such data is expected to carry critical importance in using mutational signatures for 
prognostication and for predicting response to targeted therapies. In addition, blood-derived 
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ctDNA analysis is amenable to serial assessment while on therapy in order to investigate 
acquired mutations. 
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Figure Legends 
Figure 1: Overview of Findings 
a) Number of HCC confirmed cases with alterations detected through cfDNA.  
b) Total number of alterations identified among the 181 patients with alterations, and the 
proportion of alteration types identified.  
c) Action ability among mutations identified.  
d) Total number of actionable alterations, after removing silent, VUS, and non-actionable 
mutations. 
 
Figure 2: Most frequently mutated genes identified in cfDNA among HCC patients. 
a) Distribution of all alterations identified, actionable and non-actionable genes. 
b) Proportion of patients with alterations in actionable genes only. 
c) Gene correlation matrix among all patients with alterations detected. All patients with 
alterations detected, irrespective of the actionability of the alteration (i.e. variant in non-
actionable genes, VUS, and/or synonymous) were considered for this matrix. In all from 
181 patients and 62 genes were evaluated with Spearman’s rank correlation and 
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displayed in the correlation matrix above. Non-significant correlations are marked with 
“blank” in the graph. Values < 0 indicate no agreement, 0 – 0.20 slight agreement, 0.21 
– 0.40 fair agreement, 0.41 – 0.60 as moderate agreement, 0.61 – 0.80 as substantial 
agreement, and 0.81 – 1 as almost perfect agreement. 
d) Gene correlation matrix among HCC patients with alterations in actionable genes 
(synonymous and VUS alteration excluded). Exclusion of non-actionable genes, VUS, 
and synonymous alterations reduced the patient population size considered for this 
matrix from 181 to 103 patients and from 62 genes to only 36 actionable genes. The 
correlation between mutated genes was evaluated with Spearman’s rank correlation and 
displayed in the correlation matrix above. Non-significant correlations are marked with 
“blank” in the graph. Values < 0 indicate no agreement, 0 – 0.20 slight agreement, 0.21 
– 0.40 fair agreement, 0.41 – 0.60 as moderate agreement, 0.61 – 0.80 as substantial 
agreement, and 0.81 – 1 as almost perfect agreement. 
 
Figure 3: Stratification of patients for analysis over a period of approximately 2 years. 219 
patients from various institutions underwent biopsy-free, next generation sequencing. We 
collected additional risk factor information for 102 patients, irrespective of alterations detected or 
not. Two correlation matrices were generated, independent of risk factor information. The first 
considered all patients, and all alteration types (Fig 3a, n=181 patients), and the second 
considered only patients with at least 1 alteration in an actionable gene and excluded VUS and 
synonymous alterations (Fig 3b, n=103 patients) 
 
Figure 4: Representative molecular landscape among patients with available risk factor data. 
a) Distribution of all alterations identified, actionable genes only, by alteration. 
b) Distribution of all alterations identified, actionable genes only, by patient. 
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Figure 5: Correlation between molecular landscape and risk factors contributing to HCC. Heat 
map dendrogram was generated to explore and visualize the gene mutation/amplification 
relationship along with the corresponding various risk factors. The relationship between gene 
types with regard to mutation and amplification, synonymous and targetable status was 
evaluated with Spearman’s rank correlation and displayed in the correlation matrix in which the 
non-significant correlations are marked with “blank” in the graph. 
 
Figure 6:  Correlation between molecular landscape and metabolic syndrome and/or history of 
hepatitis. 
a) Correlation with metabolic syndrome: A significant number of patients with metabolic 
syndrome, 30% (3/10) had alterations detected in PDGFRA (p=0.0113), while patients 
without metabolic syndrome (n=30) had no alterations in this gene. 
b)  Correlation with hepatitis B status: A significant number of patients with hepatitis B 
35.7% (5/9) had alterations in ERBB2 (p=0.0365), while HBV-negative patients had 
none. 
c)  Correlation with hepatitis C status: 16.7% (3/18) of patients with hepatitis C (HCV) had 
alterations in BRCA1 (p=0.0472), while HCV-negative patients had none.  
d) Correlation with Child-Pugh score:  23.1% (3/13) of patients with Child-Pugh score B had 
alterations in PIK3CA (p=0.0341), versus 0% (0/27) Score A or C (0/1) (p=0.03). 
 






